Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833108 | 0.80 | ADORA1 (0.39) | HPGDKDM4ELMNAADORA1MAPK1 | |
| SCHEMBL7478159 | 0.77 | MAP3K5 (0.45) | LMNAADORA1MEN1KMT2AMAPT | |
| SCHEMBL921576 | 0.76 | L3MBTL1 (0.54) | HPGDKDM4ELMNAADORA1NPSR1 | |
| SCHEMBL30485981 | 0.74 | RAB9A (0.68) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL126159 | 0.74 | RAB9A (0.68) | SMN1; SMN2MEN1KMT2ATP53MAPT | |
| SCHEMBL7477975 | 0.72 | MAP3K5 (0.40) | ADORA1ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL8459589 | 0.72 | NOS1 (0.43) | LMNAADORA1MEN1KMT2A | |
| SCHEMBL7474902 | 0.72 | HSD17B14 (0.42) | ADORA1MEN1KMT2ATP53MAPT | |
| SCHEMBL2144361 | 0.71 | KDM4E (0.50) | KDM4ELMNAADORA1MAPK1ALDH1A1 | |
| SCHEMBL7480623 | 0.71 | ADORA1 (0.39) | LMNAADORA1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012078-B2 | 2-aminopyridines containing fused ring substituents | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1007520-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PROD INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | LOWE JOHN ADAMS (US) | 2001-12-06 | — | — | US | disclosed |
| EP-1007520-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010339-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149017-A1 | 2-Aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | HPGD 246/4885KDM4E 1934/4885LMNA 3027/4885 |
| US-20010049379-A1 | 2-aminopyridines containing fused ring substituents | NOS2, NOS1, NOS3 | HPGD 246/4885KDM4E 1934/4885LMNA 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.